A research team from Pennsylvania State University in the United States has successfully developed an innovative implantable bioelectronic device termed the 'bionic fusion' device. This device is designed to attach seamlessly to arteries, offering a groundbreaking therapeutic option for patients suffering from drug-resistant hypertension. During animal trials, the device demonstrated its ability to significantly reduce blood pressure, achieving an average decrease of over 15% by stimulating carotid baroreceptors with microcurrents, all while avoiding any tissue damage.

The device boasts a fully flexible 3D-printed structure, primarily constructed from hydrogel. This material not only facilitates the conduction of electrical currents but also ensures a secure adherence to the blood vessel wall. Such design effectively mitigates the risks of displacement or vascular injury, issues commonly associated with traditional implants due to the dynamic nature of arterial pulsation.

Key components of the device include conductive electrodes and an adhesive film, contributing to its compact and stretchable form. The related research findings have been published in the esteemed journal 'Device'. Currently, the team is focused on refining the device's stability and fine-tuning the electrical stimulation parameters, with the ultimate goal of progressing to human clinical trials.